SVB Leerink Adjusts Recursion Pharmaceuticals' Price Target to $32 from $30, Keeps Outperform Rating

12/08/2021 | 09:47am

This article is reserved for subscribers A "one-stop shopping" service for investors The best opportunities, portfolios, and screeners Discover